Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.Barrons • 06/17/25
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reportsReuters • 06/16/25
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years24/7 Wall Street • 06/16/25
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy SolutionsPRNewsWire • 06/16/25
Eli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?The Motley Fool • 06/15/25
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)24/7 Wall Street • 06/12/25
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?Zacks Investment Research • 06/11/25
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle HealthGlobeNewsWire • 06/11/25
Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/10/25
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?24/7 Wall Street • 06/09/25
20 stocks of companies that have improved profit margins and are expected to grow quicklyMarket Watch • 06/09/25